Akeso and Summit announced updated Phase 3 overall survival data for ivonescimab, a PD-1xVEGF bispecific, after an interim OS update previously dented investor confidence. The companies said the trial cleared its OS bar in certain lung cancer patient populations, following the updated analysis. The update reinforces the market sensitivity around overall survival in oncology bispecifics, particularly when interim reads shift expectations for confirmatory development. It also puts additional pressure on competitors targeting the same biomarker-defined segments and lines of therapy. While full trial details weren’t included in the announcement, the company’s claim of OS success is designed to restore momentum toward potential regulatory and commercialization planning.